TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05131464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310, 300 mg/2 mL, SC, every 2 weeks
Study: NCT06016634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate Sodium
Description: Administer oral alendronate 70 mg once a week x 24 weeks to all study participants
Study: NCT06229288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections.~Amoxicillin PO: The dose is two capsule of 500 mg every 8 hours (that is 3 times daily).~Amoxicillin IV: The dose is 1 g every 8 hours (that is 3 times daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulanate
Description: Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections.~Amoxicillin/clavulanate PO: The dose is two tablets of 500 mg/62.5 mg every 8 hours (that is 3 times daily, approved standard dose) Amoxicillin/clavulanate IV: The dose is 1 g/200 mg every 8 hours (that is 3 times daily, approved standard dose)
Study: NCT05476055

Intervention type: GENETIC
Intervention: NGS
Description: In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children

Intervention type: GENETIC
Intervention: NGS
Description: In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
Study: NCT05032066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-825
Description: Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-825
Description: Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants who received matching placebo in the Core Phase will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks.
Study: NCT05826288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioIntelliSense BioButton Rechargable
Description: This study uses the BioIntelliSense BioButton Rechargeable for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memora Health two-way patient engagement platform provided by RC
Description: The Memora Health platform is designed to automate complex care workflows, making them simple for patients and clinicians to navigate. It utilizes a multi-modal communications system that primarily relies on two-way text messaging and artificial intelligence.
Study: NCT05476055

Intervention type: GENETIC
Intervention: NGS
Description: In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
Study: NCT04976803

Intervention type: OTHER
Intervention: Determination of ATM alteration status.
Description: ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

Intervention type: OTHER
Intervention: Determination of ATM alteration status.
Description: ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

Intervention type: OTHER
Intervention: Determination of ATM alteration status.
Description: ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
Study: NCT05239000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: geriatric co-management
Description: Geriatric co-management involves a consultation with a geriatrician prior to initiating head and neck radiation and chemotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: geriatric guided supportive care
Description: Geriatric guided supportive care will be carried out by oncologists. After the patient completes the eRFA, an automated report is generated that identifies the patient's geriatric deficits.
Study: NCT06307470

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMBRACE (Empowerment through Mind and Body Reclamation After Cancer Experience)
Description: The intervention will be led by a registered nurse who holds certifications in sexuality counseling and sex education. The therapeutic, online environment will serve as a confidential, private space without judgement to encourage discussion to model safe sexuality communication for breast cancer survivors. The curriculum will include: i) psychoeducation: sexual body, mind-body connection, and sexual relationships; ii) physical-body education: physical response, safety, and navigating physical changes in survivorship; iii) solution-focused tools: tailored vaginal rehydration, lubrication, education; and iv) communication: internal, partnered, and patient-provider communication skills.~The solution-focused tools will include vaginal rehydration and dilation products with vaginal lubrication. Tools will be distributed via mail by Session 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMBRACE (Empowerment through Mind and Body Reclamation After Cancer Experience)
Description: The intervention will be led by a registered nurse who holds certifications in sexuality counseling and sex education. The therapeutic, online environment will serve as a confidential, private space without judgement to encourage discussion to model safe sexuality communication for breast cancer survivors. The curriculum will include: i) psychoeducation: sexual body, mind-body connection, and sexual relationships; ii) physical-body education: physical response, safety, and navigating physical changes in survivorship; iii) solution-focused tools: tailored vaginal rehydration, lubrication, education; and iv) communication: internal, partnered, and patient-provider communication skills.~The solution-focused tools will include vaginal rehydration and dilation products with vaginal lubrication. Tools will be distributed via mail by Session 2.
Study: NCT05954585

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Emergency department treatment as usual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Navigator
Description: Family Navigator will speak with families about individual and systemic issues for linkage to mental health care biweekly for 3 months or until the youth's first mental health appt has been attended, whichever comes first.
Study: NCT05804019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional and physical interventions
Description: The intervention is developed with a focus on nutritional needs and physical activities. The Plan-Do-Study-Act (PDSA) model is used to redefine issues and relevant actions together with residents, relatives, care staff, and nursing home management. The intervention will be developed based on new knowledge from sub-study 1, previous studies, practical experiences, the participant's experiences and wishes as well as the staff's experiences and wishes. Together they will form an implementation catalog, from here, the intervention nursing homes can select a relevant number of components, which will be tested and implemented in practice. The implementation duration is 6 months and the PDSA model is repeated at two-month intervals to strengthen and qualify the intervention. The PDSA model is known to the city's staff in advance and is additionally used in connection to continuing education. The Usual Care Group will continue the usual care.
Study: NCT04821453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: NAVA mode of mechanical ventilation provide the trigger for a spontaneous breath from the diaphragmatic movement instead of diaphragm and allows the patient to control the dynamics of the breath generally set in CMV mode.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CMV
Description: CMV mode of mechanical ventilation that provides a trigger for a spontaneous breath from the airway flow sensor with dynamics of the breath set as required by the mode
Study: NCT05983991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples (blood and bone marrow samples).
Description: For each included patient, biological samples (blood and bone marrow samples) will be collected at baseline visit and then during 5 years, according to the samples taken in the standard practice. No additional sampling will be performed for the study.
Study: NCT06093295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation)
Description: The repetitive transcranial magnetic stimulation device will generate successive magnetic pulses to the left dorsolateral prefrontal cortex (experimental condition) and the vertex (control condition).~The theta burst stimulation protocol is as follows:~* Total stimulation time \~190 seconds~* Intensity: 80% of active motor threshold~* 2 seconds train, repeated every 10 seconds~* In every 2-second train, 3 pulses of stimulation are delivered at 50 Hz, repeated every 200 milliseconds (i.e., 5 Hz) for a total of 600 pulses

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation)
Description: The repetitive transcranial magnetic stimulation device will generate successive magnetic pulses to the left dorsolateral prefrontal cortex (experimental condition) and the vertex (control condition).~The theta burst stimulation protocol is as follows:~* Total stimulation time \~190 seconds~* Intensity: 80% of active motor threshold~* 2 seconds train, repeated every 10 seconds~* In every 2-second train, 3 pulses of stimulation are delivered at 50 Hz, repeated every 200 milliseconds (i.e., 5 Hz) for a total of 600 pulses
Study: NCT06323954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tVNS stimulation
Description: Electrical stimulation to the vagus nerve area.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Electrical stimulation to the non-vagus nerve area.
Study: NCT05795816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testofen
Description: Twice daily dose of 1 capsule (300mg per capsule Testofen)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: Twice daily dose of 1 capsule
Study: NCT05790837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer prompt Stand up for your Health®
Description: The intervention group consists on the implementation of a desktop application Stand up for your Health® computer prompt following the model proposed by the Guide to Physical Activity at Work (34). This app works by showing reminders and asking users to pause their work activity and take an active break. Pauses can be customized and programmed according to the user's preference, allowing control of the time of each pause, between pauses, and the possibility of delaying or interrupting the pause. In this study, the Stand up for your Health® app will be scheduled to appear every 60 minutes on the workers' computers and each break will last for 2 minutes. During this resting period, the worker will see a notice or reminder on their screen with a countdown clock. The application allows you to postpone or interrupt directions.
Study: NCT06223503

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transitional Pain Service
Description: The Transitional Pain Service (TPS) is a novel perioperative surgical home approach that consists of comprehensive pain management and care coordination before, during and for at least 6-months after surgery for Veterans at risk for chronic opioid use (COU).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional Pain Service
Description: The Transitional Pain Service (TPS) is a novel perioperative surgical home approach that consists of comprehensive pain management and care coordination before, during and for at least 6-months after surgery for Veterans at risk for chronic opioid use (COU).
Study: NCT05337826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: Participants will enroll in a series of remote educational visits conducted by CDCES to assess readiness and barriers to CGM initiation and utilization, with the goal to sustain use of CGM Technology over time in older populations on complex insulin regimen.
Study: NCT05434845

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: An additional 8 mL of blood will be drawn during routine lab collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: An additional 8 mL of blood will be drawn during routine lab collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: An additional 8 mL of blood will be drawn during routine lab collection
Study: NCT04897425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindful SensoriMotor Therapy Enhanced with Brain Modulation
Description: Hardware and software for myoelectric pattern recognition and sensory training developed at the Center for Bionics and Pain Research.~tES by Neuroelectrics
Study: NCT05818683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-78278343
Description: JNJ-78278343 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel will be administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AAP)
Description: Abiraterone acetate plus prednisone (AAP) will be administered orally.
Study: NCT04972721

Intervention type: OTHER
Intervention: No treatment given
Description: The study is non-interventional with no study-specific treatment during the study and the patients will be treated as per Treating Physician's and patient's own discretion.
Study: NCT04713267

Intervention type: DEVICE
Group type: OTHER
Intervention: ISABel Bed 1
Description: During the intervention nights (2 out of 3 experiment nights), positional therapy by means of the automated bed will be applied in order to induce a change in the sleeping position.
Study: NCT05787808

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calsium, Vitamin D, Jarlsberg cheese
Description: Oral

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calsium, Vitamin D, Jarlsberg cheese
Description: Oral
Study: NCT05620732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Claudin18.2 CAR-T cells
Description: patients treated with Claudin18.2 CAR-T cells
Study: NCT05522205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regulated cannabis access in pharmacies
Description: The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.
Study: NCT05376371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CJC-TraC
Description: CJC-TraC utilizes a nurse case manager (NCM) to coordinate the participant's transitional care through release from a correctional facility. The NCM will visit either in person or via telehealth with the participant up to 4 times while incarcerated, and up to 4 times after release.
Study: NCT05911048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
Description: boost with Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)
Description: boost with Recombinant COVID-19 vaccine (Sf9 Cell) (WSK-V101)
Study: NCT06059391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT with donor peripheral blood stem cells

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT with donor peripheral blood stem cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Undergo stem cell mobilization with G-CSF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granulocyte Colony-Stimulating Factor
Description: Undergo stem cell mobilization with G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation Conditioning Regimen
Description: Receive pre transplant conditioning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hematopoietic Cell Transplantation Conditioning Regimen
Description: Receive pre transplant conditioning

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pheresis
Description: Undergo apheresis

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pheresis
Description: Undergo apheresis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem Cell Mobilization Therapy
Description: Undergo stem cell mobilization with G-CSF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stem Cell Mobilization Therapy
Description: Undergo stem cell mobilization with G-CSF
Study: NCT05152134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief On-Demand
Description: Tailored interactive digital health treatment for chronic pain

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: The HE digital intervention is roughly 65 minutes with content discussing pain and health topics generally; it is devoid of pain education, psychological skills, and has no active strategies, worksheets, or supportive tools.
Study: NCT04833270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KM non-pharmacological treatment group
Description: This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological treatment group
Description: This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
Study: NCT04880798

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 124I PET/CT
Description: The first 124I PET/CT was prepared with endogenous thyrotropin 30±10 μIU/mL, and the second 124I PET/CT was prepared with endogenous thyrotropin \>100 μIU/mL. The RAI-avidity of the metastases was assessed twice along with the levothyroxine withdrawal by 124I PET/CT scans.
Study: NCT05780814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Description: The CBT-I intervention is a 6-session intervention spread out over 8 weeks that combines education and behavioral techniques to reduce insomnia.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education Control (EDU)
Description: Subjects will be instructed to read and review select publications from the American Academy of Sleep Medicine